Patrick O'Brien, COO and General Counsel at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 66,368 shares at $19.69 ($1.3M) on 2025-01-06, disclosed to the SEC on 2025-01-07.
Scheduled sale ($1.3M) by COO and General Counsel under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.69 | 19,658 | $387K | 29.4% |
| 2 | $19.69 | 19,658 | $387K | 29.4% |
| 3 | $20.10 | 9,526 | $191K | 14.6% |
| 4 | $20.10 | 9,526 | $191K | 14.6% |
| 5 | $19.69 | 8,000 | $158K | 12.0% |
| Total | $19.81 avg | 66,368 |
| $1.3M |
| 100% |
| Filing → |
| GLRE | SELL | 2025-05-14 | $267K | — | Filing → |
| ARWR | SELL | 2024-01-05 | $1.9M | — | Filing → |
| ARWR | SELL | 2023-01-06 | $280K | — | Filing → |